LEXARIA BIOSCIENCE CORP. Revenue
LEXARIA BIOSCIENCE CORP. (LEXX) reported Revenue of $0 for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. revenues for the quarter ending 2026-05-31 was $0.00, a 100.00% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. revenues for the quarter ending 2026-02-28 was $20.00K, a 88.51% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. revenues for the quarter ending 2025-11-30 was $0.00, a 100.00% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. revenues for the quarter ending 2025-08-31 was $174.00K, a 107.14% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. revenues for fiscal 2025 was $705.92K, a 52.05% increase from fiscal 2024.
- LEXARIA BIOSCIENCE CORP. revenues for fiscal 2024 was $464.28K, a 105.24% increase from fiscal 2023.
- LEXARIA BIOSCIENCE CORP. revenues for fiscal 2023 was $226.21K, a 11.43% decline from fiscal 2022.
- LEXARIA BIOSCIENCE CORP. revenues for fiscal 2022 was $255.40K, a 64.66% decline from fiscal 2021.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month |
|---|---|---|---|---|---|---|---|
| 2026-05-31 | $0.00 10-Q · filed 2026-07-13 | $20.00K derived: sum of 2 quarters · filed 2026-07-13 | $20.00K 10-Q · filed 2026-07-13 | $194.00K derived: sum of 4 quarters · filed 2026-07-13 | |||
| 2026-02-28 | $20.00K 10-Q · filed 2026-04-13 | $20.00K 10-Q · filed 2026-04-13 | $194.00K derived: sum of 3 quarters · filed 2026-04-13 | $368.00K derived: sum of 4 quarters · filed 2026-07-13 | |||
| 2025-11-30 | $0.00 10-Q · filed 2026-01-13 | $174.00K derived: sum of 2 quarters · filed 2026-01-13 | $348.00K derived: sum of 3 quarters · filed 2026-07-13 | $522.00K derived: sum of 4 quarters · filed 2026-07-13 | |||
| 2025-08-31 | $174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | $348.00K derived: sum of 2 quarters · filed 2026-07-13 | $522.00K derived: sum of 3 quarters · filed 2026-07-13 | $705.92K 10-K · filed 2025-11-28 | |||
| 2025-05-31 | $174.00K 10-Q · filed 2026-07-13 | $348.00K derived: sum of 2 quarters · filed 2026-07-13 | $531.92K 10-Q · filed 2026-07-13 | $615.92K derived: sum of 4 quarters · filed 2026-07-13 | |||
| 2025-02-28 | $174.00K 10-Q · filed 2026-04-13 | $357.92K 10-Q · filed 2026-04-13 | $441.92K derived: sum of 3 quarters · filed 2026-04-13 | $525.92K derived: sum of 4 quarters · filed 2026-04-13 | |||
| 2024-11-30 | $183.92K 10-Q · filed 2026-01-13 | $267.92K derived: sum of 2 quarters · filed 2026-01-13 | $351.92K derived: sum of 3 quarters · filed 2026-01-13 | $496.92K derived: sum of 4 quarters · filed 2026-01-13 | |||
| 2024-08-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | $168.00K derived: sum of 2 quarters · filed 2025-11-28 | $313.00K derived: sum of 3 quarters · filed 2025-11-28 | $464.28K 10-K · filed 2025-11-28 | |||
| 2024-05-31 | $84.00K 10-Q · filed 2025-07-14 | $229.00K derived: sum of 2 quarters · filed 2025-07-14 | $380.28K 10-Q · filed 2025-07-14 | $411.02K derived: sum of 4 quarters · filed 2025-07-14 | |||
| 2024-02-29 | $145.00K 10-Q · filed 2025-04-14 | $296.28K 10-Q · filed 2025-04-14 | $327.02K derived: sum of 3 quarters · filed 2025-04-14 | $404.73K derived: sum of 4 quarters · filed 2025-04-14 | |||
| 2023-11-30 | $151.28K 10-Q · filed 2025-01-10 | $182.02K derived: sum of 2 quarters · filed 2025-01-10 | $259.73K derived: sum of 3 quarters · filed 2025-01-10 | $279.75K derived: sum of 4 quarters · filed 2025-01-10 | |||
| 2023-08-31 | $30.74K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $108.45K derived: sum of 2 quarters · filed 2024-11-26 | $128.47K derived: sum of 3 quarters · filed 2024-11-26 | $226.21K 10-K · filed 2024-11-26 | |||
| 2023-05-31 | $77.71K 10-Q · filed 2024-07-12 | $93.15K 10-Q · filed 2023-07-14 | $97.73K derived: sum of 2 quarters · filed 2024-07-12 | $195.47K 10-Q · filed 2024-07-12 | $229.64K 10-Q · filed 2023-07-14 | $306.62K derived: sum of 4 quarters · filed 2024-07-12 | |
| 2023-02-28 | $20.02K 10-Q · filed 2024-04-09 | $35.02K 10-Q · filed 2023-04-14 | $117.76K 10-Q · filed 2024-04-09 | $136.49K 10-Q · filed 2023-04-14 | $228.91K derived: sum of 3 quarters · filed 2024-04-09 | $328.63K derived: sum of 4 quarters · filed 2024-04-09 | |
| 2022-11-30 | $97.73K 10-Q · filed 2024-01-12 | $101.48K 10-Q · filed 2023-01-17 | $208.88K derived: sum of 2 quarters · filed 2024-01-12 | $308.60K derived: sum of 3 quarters · filed 2024-01-12 | $339.25K derived: sum of 4 quarters · filed 2024-01-12 | ||
| 2022-08-31 | $111.15K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-20 | $210.87K derived: sum of 2 quarters · filed 2023-11-20 | $241.52K derived: sum of 3 quarters · filed 2023-11-20 | $255.40K 10-K · filed 2023-11-20 | |||
| 2022-05-31 | $99.72K 10-Q · filed 2023-07-14 | $130.37K derived: sum of 2 quarters · filed 2023-07-14 | $144.25K 10-Q · filed 2023-07-14 | $175.27K derived: sum of 4 quarters · filed 2023-07-14 | |||
| 2022-02-28 | $30.65K 10-Q · filed 2023-04-14 | $44.53K 10-Q · filed 2023-04-14 | $75.55K derived: sum of 3 quarters · filed 2023-04-14 | $279.61K derived: sum of 4 quarters · filed 2023-04-14 | |||
| 2021-11-30 | $13.88K 10-Q/A · filed 2023-01-18 | $44.90K derived: sum of 2 quarters · filed 2023-01-18 | $248.96K derived: sum of 3 quarters · filed 2023-01-18 | $440.96K derived: sum of 4 quarters · filed 2023-01-18 | |||
| 2021-08-31 | $31.02K derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | $235.08K derived: sum of 2 quarters · filed 2022-11-28 | $427.08K derived: sum of 3 quarters · filed 2022-11-28 | $722.74K 10-K · filed 2022-11-28 | |||
| 2021-05-31 | $204.06K 10-Q · filed 2022-07-14 | $396.06K derived: sum of 2 quarters · filed 2022-07-14 | $691.72K 10-Q · filed 2022-07-14 | ||||
| 2021-02-28 | $192.01K 10-Q · filed 2022-04-11 | $487.66K 10-Q · filed 2022-04-11 | |||||
| 2020-11-30 | $295.66K 10-Q · filed 2022-01-14 | ||||||
| 2020-08-31 | $314.79K 10-K · filed 2021-11-29 | ||||||
| 2018-05-31 | $140.34K 10-Q · filed 2018-07-13 | $312.30K derived: sum of 2 quarters · filed 2018-07-13 | $336.93K 10-Q · filed 2018-07-13 | ||||
| 2018-02-28 | $171.96K 10-Q · filed 2018-04-12 | $196.59K 10-Q · filed 2018-04-12 | |||||
| 2017-11-30 | $24.64K 10-Q · filed 2018-01-12 | ||||||
| 2017-05-31 | $29.25K 10-Q · filed 2018-07-13 | $41.85K derived: sum of 2 quarters · filed 2018-07-13 | $51.08K 10-Q · filed 2018-07-13 | ||||
| 2017-02-28 | $12.60K 10-Q · filed 2018-04-12 | $21.83K 10-Q · filed 2018-04-12 | |||||
| 2016-11-30 | $9.22K 10-Q · filed 2018-01-12 | ||||||
| 2016-05-31 | $6.21K 10-Q · filed 2017-07-14 | $21.37K derived: sum of 2 quarters · filed 2017-07-14 | $32.16K 10-Q · filed 2017-07-14 | ||||
| 2016-02-29 | $15.15K 10-Q · filed 2017-04-14 | $25.94K 10-Q · filed 2017-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |